September 19, 2020
“You should trust your instincts if you’re nervous because of the wobbly action in the S&P 500 Index SPX, -1.11%, Nasdaq COMP, -1.07% and the Dow Jones Industrial Average DJIA, -0.87% since these indices got slammed in early September. Starting right about now, the stock market will see a… Continue Reading…
September 19, 2020
“Bellicum Pharmaceuticals (BLCM)… Looking at the consensus breakdown, 2 Buys and no Holds or Sells have been published in the last three months. Therefore, BLCM gets a Moderate Buy consensus rating. Based on the $21.50 average price target, which is… Continue Reading…
September 18, 2020
“With some stocks carving out durable bottoming patterns, here are 3 Nasdaq stocks to buy: Netflix (NASDAQ:NFLX) Vertex Pharmaceuticals (NASDAQ:VRTX) First Solar (NASDAQ:FSLR) But bear in mind the Nasdaq and lopsided influencers Apple (NASDAQ:AAPL), Microsoft (NASDAQ:MSFT) and Amazon (NASDAQ:AMZN) still have more base building to do before a truly… Continue Reading…
September 18, 2020
“HBT Financial (HBT)… Tamayo’s is one of two reviews on this stock. The other gives a Hold, making the analyst consensus rating a Moderate Buy. The $15.50 average price target suggests that there is room for 29% growth from the trading… Continue Reading…
September 17, 2020
“Aquestive Therapeutics (AQST)… All in all, other analysts echo Moussatos’ sentiment. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. With an average price target of $18.67, the upside potential comes in at 136%…… Continue Reading…
September 17, 2020
“Akero Therapeutics (AKRO)… Are other analysts in agreement? They are. Only Buy ratings, 6, in fact, have been issued in the last three months. Therefore, the message is clear: AKRO is a Strong Buy. Given the $58.50 average price target,… Continue Reading…
September 16, 2020
“Southwest Airlines (LUV)… In line with his optimism, Shanker rates LUV an Overweight (i.e. Buy). His $54 price target implies a 33% upside for the stock in the coming year… Delta Airlines, Inc. (DAL)… Overall, the analyst consensus on Delta is a… Continue Reading…
September 16, 2020
“MediWound Ltd. (MDWD)… To this end, DeGeeter rates MDWD an Outperform along with a $7 price target. Should his thesis play out, a potential twelve-month gain of 117% could be in the cards… UroGen Pharma (URGN)… To this end, Gershell… Continue Reading…
September 15, 2020
“Venus Concept (VERO)… To this end, Thibault rates VERO a Buy along with a $7 price target. This target conveys the analyst’s confidence in VERO’s ability to climb 231% higher from current levels… Minerva Neurosciences (NERV)… What does the rest… Continue Reading…
September 15, 2020
“Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead’s availability of cancer treatments, the companies announced on Sunday. Shares of Immunomedics surged more than 100% in premarket trading Monday. The deal will provide Gilead access to the drug Trodelvy, a… Continue Reading…
Recent Comments